Found 324 articles
YishengBio Co., Ltd. and Summit Healthcare Acquisition Corp. announced that they have entered into a definitive agreement for a business combination of Summit and the Company.
ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update
ZyVersa Therapeutics, Inc. and Larkspur Health Acquisition Corp. are pleased to announce that Larkspur has refiled with the U.S. Securities and Exchange Commission their proxy/registration statement on Form S-4 in connection with the business combination agreement between Larkspur and ZyVersa previously announced on July 20, 2022.
Epiphany Technology Acquisition Corp. (the "Company") announced today that the company's Board of Directors (the "Board") has approved an increase in the size of the Board from seven (7) directors to eleven (11) directors and elected Ross Haghighat, Stephen Sherwin, Ronald Eastman and Louis Lange as members of the Board.
Several biotech companies backed by billions are working on different approaches to developing the next big anti-aging therapy - from blood experiments to cell reprogramming.
Building on Their Innovative mRNA Vaccine Program, Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) Recently Announced Business Combination to Support the Discovery of a New Class of Antimalarial Drugs.
Ocean Biomedical and Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) recently announced business combination, once closed, will further Ocean Biomedical’s work on the discovery of a whole new class of antimalarial drugswhich target PfGARP and kill malaria parasites.
Immunis Inc., a private biotechnology company developing an immunomodulatory secretome for age and disease-related immune decline in Phase 1/2a testing, welcomes Peter H. Diamandis, M.D. to the Executive Advisory Board.
Suneva Medical Launches 30 mL PRP Gel Tubes of Amplifine, Allowing for More Variety and Efficiency in PRP Treatments
Suneva Medical, Inc. ("Suneva" or the "Company") today launched the 30 mL iteration of their Amplifine Platelet Rich Plasma (PRP) gel tubes, which will provide patients and practices with a larger volume of PRP to address varying areas of concern more efficiently.
Aesther Healthcare Acquisition Corp. Announces Intention to Extend Period to Consummate Business Combination
As previously announced, on August 30, 2022, Aesther Healthcare Acquisition Corp. entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced that its Board of Directors has approved an extension of the period of time available to Aesther to consummate a business combination by three months from September 16, 2022 to December 16, 2022, as permitted under Aesther’s governing documents.
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common Stock Purchase Transaction with White Lion Capital
Aesther Healthcare Acquisition Corp, a special purpose acquisition company has entered into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a next-generation biopharma company.
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors Which Kill Glioblastoma and Block the Metastasis of Malignant Melanoma Cells to the Lung By Over 90% Announced by Ocean Biomedical and Aesther Healthcare (NASDAQ: AEHA)
Ocean Biomedical and Aesther Healthcare Acquisition Corp. announced the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%.
AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, announced the appointment of Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer, effective September 1, 2022.
Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ
Aesther Healthcare Acquisition Corp (NASDAQ; AEHA) (“Aesther”), a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, or similar business combination with one or more businesses, today announced that it has entered into an Agreement and Plan of Merger with Ocean Biomedical, Inc. (“Ocean Biomedical”), a next-generation biopharma company, (the “Merger Agreement”).
DiamiR Biosciences Expands Management Team with the Appointment of Fred Knechtel as its Chief Financial Officer
DiamiR today announced the expansion of its management team by the appointment of Fred Knechtel as Chief Financial Officer (CFO), effective immediately.
ProSomnus® Sleep Technologies Announces Signing of Definitive Agreements for $30 Million of Convertible Notes
ProSomnus Sleep Technologies ("ProSomnus"), the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the execution of definitive agreements with institutional investors led by funds affiliated with or managed by Cohanzick Management, LLC and CrossingBridge Advisors, LLC
GLO PHARMA APPOINTS CURRENT EXECUTIVE CHAIRMAN OF THE BEAUTY HEALTH COMPANY AND FORMER ALLERGAN PLC CEO BRENT SAUNDERS TO ITS BOARD OF DIRECTORS
GLO Pharma, the parent company of breakthrough subtopical skincare brand Ourself, today announces the appointment of Brent Saunders to its Board of Directors.
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI® (teclistamab) as monotherapy for the treatment of patients with relapsed or refractory (R/R) multiple myeloma.
Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics
Larkspur Health Acquisition Corp. and ZyVersa Therapeutics, Inc. are pleased to announce that Larkspur has filed with the U.S. Securities and Exchange Commission a registration statement on Form S-4 in connection with the business combination agreement between Larkspur and ZyVersa previously announced on July 20, 2022.
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today reported its second quarter 2022 financial results and highlighted recent corporate progress.
Better Therapeutics, Inc. today reported financial results for the second quarter of 2022 and provided an update on progress toward achieving key corporate milestones.
OceanTech Acquisitions I Corp. and Captura Biopharma, Inc. Announce Signing of Definitive Business Combination Agreement
Captura Biopharma, Inc. is developing oral chelators for the treatment of internal transuranic radionuclide contamination and heavy metal poisoning.